EQS-News

PharmaSGP exceeds the € 100 million revenues mark in 2023 and plans further profitable growth in 2024 - Seite 2

For the current 2024 financial year, the Management Board of PharmaSGP expects the success story to continue with revenues in a range between € 107.0 million and € 112.0 million. The Management Board is also forecasting a further increase in adjusted EBITDA with earnings of between € 35.0 million and € 38.0 million. This corresponds to an adjusted EBITDA margin of 32.7% to 33.9%.

PharmaSGP will publish its full annual report for 2023 on 29 April, 2024.

 

OVERVIEW OF PRELIMINARY YEAR-ON-YEAR FIGURES

Consolidated figures (in € million)	2023		2022	∆
Revenues	101.1		85.8	+17.8%
Adjusted EBITDA	34.1		28.2	+20.8%
Unadjusted EBITDA	34.0		26.9	+26.3%
Adjusted EBITDA margin	33.7%		32.9%
Unadjusted EBITDA margin	33.6%		31.4%
Revenues by region (in € million)	2023		2022	∆
Germany	73.4		61.3	+19.6%
Italy	13.6		10.5	+28.8%
Austria	10.5		9.8	+7.8%
Other European countries	3.7		4.2	-13.0%
Revenues share by region	2023		2022
Germany	72.6%		71.5%
Italy	13.4%		12.3%
Austria	10.4%		11.4%
Other European countries	3.6%		4.8%
Revenues by product category (in € million)		2023	2022	∆
Health Brands	97.5		82.5	+18.2%
Beauty Brands	3.5		3.3	+6.0%

CONTACT